IFP Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-87
| Closed | -$271 | – | 3620 |
|
|
2023
Q1 | $271 | Sell |
87
-500
| -85% | -$46 | ﹤0.01% | 3249 |
|
|
2022
Q4 | $3K | Buy |
587
+87
| +17% | +$11 | ﹤0.01% | 4092 |
|
|
2022
Q3 | $2K | Hold |
500
| – | – | ﹤0.01% | 4471 |
|
|
2022
Q2 | $2K | Hold |
500
| – | – | ﹤0.01% | 4251 |
|
|
2022
Q1 | $2K | Buy |
+500
| New | +$535 | ﹤0.01% | 4248 |
|
|
2021
Q3 | – | Sell |
-150
| Closed | -$1K | – | 3494 |
|
|
2021
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 2982 |
|
|
2021
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 2917 |
|
|
2020
Q4 | $1K | Hold |
150
| – | – | ﹤0.01% | 2852 |
|
|
2020
Q3 | $0 | Hold |
150
| – | – | ﹤0.01% | 3057 |
|
|
2020
Q2 | $0 | Hold |
150
| – | – | ﹤0.01% | 3020 |
|
|
2020
Q1 | $0 | Hold |
150
| – | – | ﹤0.01% | 3078 |
|
|
2019
Q4 | $0 | Sell |
150
-500
| -77% | -$370 | ﹤0.01% | 3201 |
|
|
2019
Q3 | $0 | Buy |
+650
| New | +$876 | ﹤0.01% | 3170 |
|
|
2019
Q1 | – | Sell |
-150
| Closed | – | – | 3643 |
|
|
2018
Q4 | $0 | Hold |
150
| – | – | ﹤0.01% | 3964 |
|
|
2018
Q3 | $0 | Hold |
150
| – | – | ﹤0.01% | 4078 |
|
|
2018
Q2 | $0 | Hold |
150
| – | – | ﹤0.01% | 4121 |
|
|
2018
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 3696 |
|
|
2017
Q4 | $1K | Sell |
150
-500
| -77% | -$1.52K | ﹤0.01% | 3748 |
|
|
2017
Q3 | $2K | Sell |
650
-125
| -16% | -$354 | ﹤0.01% | 3820 |
|
|
2017
Q2 | $2K | Hold |
775
| – | – | ﹤0.01% | 3792 |
|
|
2017
Q1 | $1K | Hold |
775
| – | – | ﹤0.01% | 3889 |
|
|
2016
Q4 | $1K | Hold |
775
| – | – | ﹤0.01% | 3879 |
|
|
2016
Q3 | $1K | Hold |
775
| – | – | ﹤0.01% | 3804 |
|
|
2016
Q2 | $2K | Buy |
+775
| New | +$1.82K | ﹤0.01% | 3520 |
|
|
2016
Q1 | – | Sell |
-775
| Closed | -$3K | – | 3635 |
|
|
2015
Q4 | $3K | Buy |
+775
| New | +$3.12K | ﹤0.01% | 3243 |
|
Other funds holding STAB
IFP Advisors's STAB Position: Q2 2023 in Review
IFP Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2023, closing a stake of 87 shares — an estimated $271 sold.
IFP Advisors first reported a position in STAB in Q4 2015 and held it in 25 quarters. The position peaked at $3K in Q4 2022. 1 fund tracked by Wall St. Rank holds STAB as of Q2 2023.
- IFP Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- IFP Advisors sold 87 Statera Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $271.
- IFP Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2015 and held it in 25 quarters.
- IFP Advisors's Statera Biopharma, Inc. Common Stock position peaked at $3K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2023.
Based on IFP Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.